概括
抗体聚合物合物 (APC) 提供了一种新的纳米医学方法,以克服抗体药物合物 (ADC) 的局限性. 这种新平台提高了药物对抗体比率 (DAR),并展示了向的癌细胞杀死能力.
科学领域:
- 纳米医学是一种纳米医学.
- 生物结合化学 生物结合化学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 抗体药物联合体 (ADCs) 在向癌症纳米医学中表现有前途.
- 由于药物对抗体比率 (DAR) 较低和生理化学不稳定性,目前的ADC面临限制.
- 这些局限性限制了ADC在癌症治疗中的疗效.
研究的目的:
- 设计抗体聚合物合物 (APC) 作为一个模块化策略,以克服ADC的局限性.
- 为了提高药物对抗体比率 (DAR) 使用聚合物结合.
- 评估APCs针对癌症细胞系的向细胞杀死功效.
主要方法:
- 聚合物基治疗分子与抗体的结合,以创建APC.
- 在聚合物中使用水友性共体,以掩盖高药负载引起的疏水性.
- 评估HER2和EGFR表达细胞系中的细胞向性和选择性细胞杀死.
主要成果:
- 该APC平台成功地提高了药物对抗体比率 (DAR).
- 抗癌药物证明了有效的细胞向性和选择性杀死癌细胞.
- 该平台的模块化允许通过不同的药物功能进行附着.
结论:
- 抗体聚合物合物 (APC) 是传统ADC的可行替代品.
- 该APC平台提供了改进的DAR和针对性治疗提供纳米医学.
- 这一战略为下一代瘤学中的活性向纳米医学提供了基础.
更多相关视频
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
7.7K
09:39Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
6.9K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Antibody Actions
1.2K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.2K
Hybridoma Technology
15.0K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.0K
Antibody Structure
60.4K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.4K
